<DOC>
	<DOCNO>NCT02068339</DOCNO>
	<brief_summary>Dithiolethiones , novel class adenosine monophosphate-activated protein kinase ( AMPK ) activator , prevent insulin resistance AMPK-dependent p70 ribosomal S6 kinase-1 ( S6K1 ) inhibition . And well know modulation S6K1 oltipraz inhibit development insulin resistance hyperglycemia AMPK-S6K1 pathway.Also research report LXRg ( member nuclear hormone receptor ) -mediated increase SREBP-1c ( sterol regulatory element-binding protein-1c gene ) promote expression lipogenic gene enhance fatty acid synthesis oltipraz inhibits LXRg SREBP-c . Therefore , Oltipraz inhibit fatty acid synthesis AMPK-S6K1 pathway LXRg-SREBP-1c pathway liver .</brief_summary>
	<brief_title>Efficacy Safety Oltipraz Liver Fat Reduction Patients With Non-Alcoholic Fatty Liver Disease Except Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Oltipraz</mesh_term>
	<criteria>Patients 19 75 year age Patients nonalcoholic fatty liver disease except cirrhosis Patients abnormal ALT , AST Patients satisfy laboratory test Patients agree contraception Patients keet diet Over 2 ratio AST ALT Type 1 diabetes mellitus ( insulindependent diabetes mellitus ) Type 2 diabetes mellitus ( control ) Disorder liver function exception nonalcoholic fatty liver Patients malignant tumor Patients take drug induce fatty liver within 8 week participation study Patients take medication could affect treatment NAFLD within 4 week Patients take Vitamin E ( â‰¥ 800 IU/day ) , thiazolidinediones , orlistat within 12 week Patients Bariatric surgery less 6 month prior participation study Patients judge investigator participation study difficult due disease follow ; Any history immune disorder Patients receive treatment may affect liver function within 1 month prior participation study Patient administer investigational product within 1 month prior participation study Patient allow get MRS test : pacemaker , shunt etc Pregnant nursing woman antiHIV antibody ( + ) Patient consider ineligible participation study Investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>